Stockreport

Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Disea...

Homology Medicines, Inc.  (FIXX) 
Last homology medicines, inc. earnings: 3/12 04:10 pm Check Earnings Report
PDF Company is planning to evaluate ADX-097 in a Phase 2 clinical trial of complement-mediated renal diseases , with initial data expected by year-end 2024 and topline resu [Read more]